Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

2008, at 3 pm CET. The dial-in numbers are:

+41(0)91-610-56-00 (Europe)

+44(0)207-107-0611 (UK)

+1(1)-866-291-4166 (USA)

The conference call (Call ID 16607, followed by the #) will be available

for play-back for 48 hours after the call by dialling:

+41(0)91-612-43-30 (Europe)

+44(0)207-108-6233 (UK)

+1(1)866-416-2558 (USA)

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The NDA-filing process for intravenous iclaprim in this indication in the USA is ongoing and expected to be completed in the next few weeks.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's f
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Personal Health Record and A Year,s Supply ... and Kissably Sweet at the White HouseLOS ... Inc. (OTC Bulletin Board: FVRL), which through ... "MMR") provides consumer-controlled Personal Health Records ("PHRs") ...
... to stockholders through liquidationA decisive victory for stockholder ... L.P. ("BVF"), today announced that stockholders of Avigen ... remove the existing Board of Directors of Avigen ... took place earlier today at the special meeting ...
... ArunA Biomedical, Inc., announced today that it will ... cells commercially available to the research community in ... stem cells, ArunA,s hMC lines will offer unique, ... a feeder free monolayer culture.(Logo: ...
Cached Biology Technology:MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 2MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 3MMR and Dancing Paws to Participate in Joint Sales Effort to Provide Personal Health Records for Pets 4Biotechnology Value Fund, L.P. Announces Overwhelming Support to Remove the Board of Directors of Avigen, Inc. at Special Meeting of Stockholders 2ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells 2
(Date:4/22/2014)... that has the same crystal structure as a mineral ... shooting up the efficiency charts faster than almost anything ... a less expensive way of using sunlight to generate ... at the Energy Department,s National Renewable Energy Laboratory (NREL) ... unique testing capabilities and broad spectrum of expertise to ...
(Date:4/22/2014)... President Barack Obama begins a trip to Asia ... pivot to the Pacific, officials at the Office ... Technology and Education Partnership (APTEP) as an example ... States and its allies in the region. , ... across the Asia-Pacific region, supports the development of ...
(Date:4/22/2014)... . , Performed ... genome and subsequent phylogenetic analysis show that the virus ... distinct from strains previously identified in the Democratic Republic ... the laboratory confirmed cases with the initial deaths recorded ... a lethal, highly contagious virus for which there is ...
Breaking Biology News(10 mins):NREL unlocking secrets of new solar material 2NREL unlocking secrets of new solar material 3NREL unlocking secrets of new solar material 4NREL unlocking secrets of new solar material 5NREL unlocking secrets of new solar material 6Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2
... published this week report findings that increase our understanding ... how the speed of its development is controlled. In ... cellular pathways that act to convey information about a ... use that information to correctly time critical transitional events ...
... is a defensive, protective reaction. This ancestral and automatic ... potential predator. A new study published in Psychophysiology finds ... encountering a threat. The mere picture of an injured ... unpleasant images, the study's participants froze as their heart ...
... at Yale have identified a gene that regulates the ... according to a recent report in the journal Cell. ... zone of dead cells around an infection site that ... of Molecular, Cellular and Developmental Biology at Yale and ...
Cached Biology News:Hormones and growth: The control of body size and developmental growth rate in fruit flies 2When in danger humans are similar to a deer in the headlights 2